Clinical Trials Browser

Interventional × Breast Neoplasms × Sirolimus × Clear all

NCT05826964 2026-01-13

Levels of Circulating Tumor DNA as a Predictive Marker for Early Switch in Treatment for Patients With Metastatic (Stage IV) Breast Cancer

Phase 2 Active not recruiting

24 enrolled

Breast

Breast Neoplasms

NCT05508906 2025-10-22

Phase 1b Study of OP-1250 (Palazestrant) in Combination With Ribociclib, Alpelisib, Everolimus, or Atirmociclib in ER+, HER2- Breast Cancer

Phase 1 Recruiting

190 enrolled

Breast

Breast Neoplasms

NCT01552434 2025-10-14

Bevacizumab and Temsirolimus Alone or in Combination With Valproic Acid or Cetuximab in Treating Patients With Advanced or Metastatic Malignancy or Other Benign Disease

Phase 1 Active not recruiting

155 enrolled

BreastCNSGenitourinaryHead & NeckLymphoidMyeloidSarcoma

Breast Neoplasms, Carcinoma, Transitional Cell, Endocrine Gland Neoplasms, Castleman Disease, Mouth Neoplasms, Neoplasm Metastasis, Neoplasms, Pharyngeal Neoplasms, Recurrence, Sarcoma, Soft Tissue Neoplasms, Thyroid Neoplasms, Urologic Neoplasms, Neurofibromatosis 2, Lymphangioleiomyomatosis, Neoplasms, Mesothelial, Erdheim-Chester Disease

NCT06957379 2025-05-04

Sirolimus for Injection (Albumin-bound) in Combination With Endocrine Therapy for HR+/HER2- Advanced/Metastatic Breast Cancer Patients Who Have Failed Standard Therapy

Phase 2 Active not recruiting

78 enrolled

Breast

Breast Neoplasms

NCT06929325 2025-04-16

Sirolimus for Injection (Albumin-bound) Combined With Fulvestrant for HR+/HER2- Advanced/Metastatic Breast Cancer Patients Previously Treated With CDK4/6 Inhibitors

Phase 3 Not yet recruiting

312 enrolled

Breast

Breast Neoplasms

NCT03878524 2024-03-04

Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME Trial

Phase 1 Terminated

2 enrolled

BreastClassical hematologyGastrointestinalGenitourinaryLymphoidMyeloidOther hematologic neoplasmPlasma cell

Anemia, Blast Crisis, Breast Neoplasms, Hodgkin Disease, Lymphoma, Non-Hodgkin, Multiple Myeloma, Myelodysplastic Syndromes, Myeloproliferative Disorders, Neoplasm Metastasis, Pancreatic Neoplasms, Prostatic Neoplasms, Thrombocytosis, Leukemia, Lymphocytic, Chronic, B-Cell, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Leukemia, Myeloid, Accelerated Phase, Leukemia, Myeloid, Chronic-Phase, Leukemia, Myeloid, Acute, Leukemia, Myelomonocytic, Chronic, Hematologic Neoplasms, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Myelodysplastic-Myeloproliferative Diseases, Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative, Primary Myelofibrosis

NCT02642094 2023-12-05

Aging Mammary Stem Cells and Breast Cancer Prevention

Phase 2 Terminated

58 enrolled 11 charts

Breast

Breast Neoplasms

NCT04736589 2021-02-03

Inetetamab Plus Rapamycin and Chemotherapy for HER2+ Metastatic Breast Cancer With Abnormal Activation of PAM Pathway

Phase 3 Not yet recruiting

270 enrolled

Breast

Breast Neoplasms

NCT00376688 2020-02-24

Temsirolimus in Treating Patients With Locally Advanced or Metastatic Breast Cancer

Phase 2 Completed

31 enrolled 5 charts

Breast

Breast Neoplasms

NCT02145559 2019-04-22

A Pharmacodynamic Study of Sirolimus and Metformin in Patients With Advanced Solid Tumors

Phase 1 Completed

24 enrolled

BreastGastrointestinalGenitourinaryLymphoidThoracic

Breast Neoplasms, Kidney Neoplasms, Liver Neoplasms, Lung Neoplasms, Lymphoma

NCT00699491 2018-06-13

Cixutumumab and Temsirolimus in Treating Patients With Locally Recurrent or Metastatic Breast Cancer

Phase 1/2 Completed

48 enrolled 14 charts

Breast

Breast Neoplasms, Breast Neoplasms, Male

NCT01797120 2018-05-30

PrE0102

Phase 2 Completed

131 enrolled 12 charts

Breast

Breast Neoplasms

NCT01390818 2017-03-07

Trial of MEK Inhibitor and PI3K/mTOR Inhibitor in Subjects With Locally Advanced or Metastatic Solid Tumors

Phase 1 Completed

146 enrolled 42 charts

BreastDermatologicGastrointestinalThoracic

Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Melanoma, Neoplasm Metastasis, Colorectal Neoplasms

NCT01522820 2016-10-04

Vaccine Therapy With or Without Sirolimus in Treating Patients With NY-ESO-1 Expressing Solid Tumors

Phase 1 Completed

18 enrolled

BreastCNSDermatologicGastrointestinalGenitourinaryGynecologicSarcomaThoracic

Astrocytoma, Urinary Bladder Neoplasms, Brain Neoplasms, Breast Neoplasms, Carcinoma, Renal Cell, Esophageal Neoplasms, Glioblastoma, Carcinoma, Hepatocellular, Lung Neoplasms, Melanoma, Oligodendroglioma, Ovarian Neoplasms, Prostatic Neoplasms, Sarcoma, Stomach Neoplasms, Colorectal Neoplasms

NCT00411788 2016-09-21

A Phase II Study of Rapamycin and Trastuzumab for Patients With HER-2 Receptor Positive Metastatic Breast Cancer

Phase 2 Completed

11 enrolled 8 charts

Breast

Breast Neoplasms

NCT01155258 2016-06-13

Temsirolimus and Vinorelbine Ditartrate in Treating Patients With Unresectable or Metastatic Solid Tumors

Phase 1 Completed

19 enrolled

BreastCNSDermatologicEndocrineGenitourinaryGynecologicThoracic

Carcinoma, Ovarian Epithelial, Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Uterine Cervical Neoplasms, Paraganglioma, Extra-Adrenal, Pheochromocytoma, Prostatic Neoplasms, Carcinoma, Merkel Cell, Endometrial Neoplasms, Carcinoma, Islet Cell, Carcinoma, Medullary, Breast Neoplasms, Male, Small Cell Lung Carcinoma

NCT00375245 2014-01-17

Rapamycin With Grapefruit Juice for Advanced Malignancies

Phase 1 Completed

41 enrolled

BreastDermatologicGastrointestinalGenitourinaryGynecologicHead & NeckLymphoidOther solid neoplasmThoracic

Urinary Bladder Neoplasms, Breast Neoplasms, Head and Neck Neoplasms, Kidney Neoplasms, Liver Neoplasms, Lung Neoplasms, Lymphoma, Melanoma, Mesothelioma, Neoplasm Metastasis, Neoplasms, Ovarian Neoplasms, Pancreatic Neoplasms, Prostatic Neoplasms, Stomach Neoplasms, Thyroid Neoplasms, Colorectal Neoplasms